OUD Med Prolongs Ketamine’s Reduction in Suicidal Ideation
A recent study found that buprenorphine can prolong the reduction of suicidal ideation in patients with major depressive disorder after ketamine treatment. The trial showed a significant decrease in suicidal thoughts among those receiving buprenorphine compared to a placebo. These findings suggest a potential new treatment strategy for reducing suicidality in depression.
- ▪Buprenorphine prolonged the reduction in suicidal ideation following ketamine treatment in patients with major depressive disorder.
- ▪Patients receiving buprenorphine experienced a 76% reduction in suicidal ideation at week 4 compared to 43% for the placebo group.
- ▪The study indicates a different biological mechanism between depression symptoms and suicidal symptoms.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/buprenorphine-may-prolong-ketamines-reduction-suicidal-2026a1000gfj?src=rss |
| Publication time | Thu, 21 May 2026 02:55:05 EDT |
| Retrieval time | 2026-05-21T07:05:03.555Z |
| Last seen | 2026-05-21T07:05:03.555Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | xspHhDZ94XfN |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
SAN FRANCISCO — Buprenorphine — a medication commonly used to treat opioid use disorder — prolonged the reduction in suicidal ideation following treatment with ketamine in patients with major depressive disorder (MDD).Results of the randomized controlled trial showed that after a single infusion with ketamine, patients given low doses of buprenorphine experienced significant decreases in suicidal ideation, with a 76% reduction at week 4 compared with 43% for placebo.This is the second trial that has shown that buprenorphine at low doses reduces suicidal ideation in MDD.“However, unlike earlier reports, the degree of reduction was enhanced markedly by pretreating with intravenous ketamine,” principal investigator Alan Schatzberg, MD, said in a press briefing.“The similarities of the…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
